WO2003072047A3 - Idothyronine compositions - Google Patents

Idothyronine compositions Download PDF

Info

Publication number
WO2003072047A3
WO2003072047A3 PCT/US2003/005526 US0305526W WO03072047A3 WO 2003072047 A3 WO2003072047 A3 WO 2003072047A3 US 0305526 W US0305526 W US 0305526W WO 03072047 A3 WO03072047 A3 WO 03072047A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
active agent
idothyronine
terminus
methods
Prior art date
Application number
PCT/US2003/005526
Other languages
French (fr)
Other versions
WO2003072047A2 (en
Inventor
Thomas Piccariello
Randal J Kirk
Lawrence P Olon
Original Assignee
New River Pharmaceuticals Inc
Thomas Piccariello
Randal J Kirk
Lawrence P Olon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/136,433 external-priority patent/US7163918B2/en
Priority claimed from US10/156,527 external-priority patent/US7060708B2/en
Application filed by New River Pharmaceuticals Inc, Thomas Piccariello, Randal J Kirk, Lawrence P Olon filed Critical New River Pharmaceuticals Inc
Priority to AU2003216382A priority Critical patent/AU2003216382A1/en
Publication of WO2003072047A2 publication Critical patent/WO2003072047A2/en
Publication of WO2003072047A3 publication Critical patent/WO2003072047A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

The present invention relates to compositions comprising an active agent. More specifically, the invention relates to active agent compositions that include a peptide carrier and an active agent covalently attached to at least one of the N-terminus, the C-terminus, a side chain of the peptide carrier, and/or interspersed within the peptide chain; methods for protecting and administering active agents; and methods for treating thyroid disorders.
PCT/US2003/005526 2002-02-22 2003-02-24 Idothyronine compositions WO2003072047A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003216382A AU2003216382A1 (en) 2002-02-22 2003-02-24 Idothyronine compositions

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US35838102P 2002-02-22 2002-02-22
US60/358,381 2002-02-22
US36625802P 2002-03-22 2002-03-22
US60/366,258 2002-03-22
US10/136,433 US7163918B2 (en) 2000-08-22 2002-05-02 Iodothyronine compositions
US10/136,433 2002-05-02
US10/156,527 2002-05-29
US10/156,527 US7060708B2 (en) 1999-03-10 2002-05-29 Active agent delivery systems and methods for protecting and administering active agents

Publications (2)

Publication Number Publication Date
WO2003072047A2 WO2003072047A2 (en) 2003-09-04
WO2003072047A3 true WO2003072047A3 (en) 2004-06-17

Family

ID=27767913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/005526 WO2003072047A2 (en) 2002-02-22 2003-02-24 Idothyronine compositions

Country Status (2)

Country Link
AU (1) AU2003216382A1 (en)
WO (1) WO2003072047A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050010756A (en) * 2002-02-22 2005-01-28 뉴 리버 파마슈티칼스, 인크. Use of peptide-drug conjugation to reduce inter-subject variability of drug serum levels
CN1649614A (en) * 2002-02-22 2005-08-03 新河药品股份有限公司 Active agent delivery systems and methods for protecting and administering active agents
CN107561168A (en) * 2016-06-30 2018-01-09 山东新时代药业有限公司 A kind of analyzing detecting method of Pegylation insulin secretion accelerating peptide analog

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489165A (en) * 1983-01-24 1984-12-18 Becton Dickinson And Company Chromogenic tracers for use in an assay
US4801504A (en) * 1985-03-18 1989-01-31 Eastman Kodak Company Fluorescent labels having a polysaccharide bound to polymeric particles
US4820860A (en) * 1986-08-25 1989-04-11 Hoechst Aktiengesellschaft Novel thyronine derivatives
US5691456A (en) * 1992-03-30 1997-11-25 Abbott Laboratories Reagents and methods for the detection and quantification of thyroxine in fluid samples
US5843634A (en) * 1993-03-09 1998-12-01 Abbott Laboratories Genetically engineered enzymes and their conjugates for diagnostic assays
US5856359A (en) * 1995-11-29 1999-01-05 Hexal Ag Thyroxine/cyclodextrin complexes and pharmaceutical compositions containing the same
US5910569A (en) * 1994-11-22 1999-06-08 Lotus Biochemical Corporation Iodothyronine polymers
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489165A (en) * 1983-01-24 1984-12-18 Becton Dickinson And Company Chromogenic tracers for use in an assay
US4801504A (en) * 1985-03-18 1989-01-31 Eastman Kodak Company Fluorescent labels having a polysaccharide bound to polymeric particles
US4820860A (en) * 1986-08-25 1989-04-11 Hoechst Aktiengesellschaft Novel thyronine derivatives
US5691456A (en) * 1992-03-30 1997-11-25 Abbott Laboratories Reagents and methods for the detection and quantification of thyroxine in fluid samples
US5843634A (en) * 1993-03-09 1998-12-01 Abbott Laboratories Genetically engineered enzymes and their conjugates for diagnostic assays
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US5910569A (en) * 1994-11-22 1999-06-08 Lotus Biochemical Corporation Iodothyronine polymers
US5856359A (en) * 1995-11-29 1999-01-05 Hexal Ag Thyroxine/cyclodextrin complexes and pharmaceutical compositions containing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ADAMCZYK ET AL.: "Immunoassay reagents for thyroid testing. 1. Synthesis of thyroxine conjugates", BIOCONJUGATE CHEMISTRY, vol. 5, no. 5, 1994, pages 459 - 462, XP000465956 *

Also Published As

Publication number Publication date
AU2003216382A8 (en) 2003-09-09
AU2003216382A1 (en) 2003-09-09
WO2003072047A2 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
WO2007030577A3 (en) Prodrugs of t3 and t4 with enhanced bioavailability
EP1401479A4 (en) Detection and therapy of vulnerable plaque with photodynamic compounds
UA85368C2 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
WO2003074551A3 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
WO2004058837A3 (en) Ampholytic copolymer and use thereof
ID29552A (en) TRIAZOLA COMPOUNDS AND ITS USE
WO2007047291A3 (en) Anti-glypican-3 antibody
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
ZA200202543B (en) Bicyclic amino acid as pharmaceutical agents.
MXPA04006039A (en) Methods for the treatment of peripheral neural and vascular ailments.
WO2000023094A3 (en) Methods of inhibiting platelet activation and recruitment
WO2004009616A3 (en) Ghrelin analogs
SG168401A1 (en) Catalyst and use thereof
MXPA05000765A (en) 5-aryltetrazole compounds, compositions thereof, and uses therefor.
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
NZ319138A (en) Composition containing cytochrome complex III and fenazaquin for combatting parasitic fungi
WO2002096348A3 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
WO2001046455A3 (en) Survivin promotion of angiogenesis
WO2002098362A3 (en) Use of rank antagonists to treat cancer
WO2003066022A3 (en) Stable pharmaceutical composition useful for treating gastrointestinal disorders
WO2002060483A3 (en) Perylenequinones for use as photosensitizers and sonosensitizers
WO2003072047A3 (en) Idothyronine compositions
IL156069A0 (en) Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma
WO2004037168A3 (en) Treatment of pancreatitis with amylin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP